fig3
From: Prognostic ability of inflammation-based markers in radioembolization for hepatocellular carcinoma
![Prognostic ability of inflammation-based markers in radioembolization for hepatocellular carcinoma](https://image.oaes.cc/95d97a06-9c1e-4152-83bf-65cd13a83297/3694.fig.3.jpg)
Figure 3. Mean NLR and PLR for non-responders and responders to TARE. The mean pre-treatment NLR was higher for non-responders than for responders (3.5 vs. 2.1, P = 0.045) (asterisk). Error bars represent the standard deviation. NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; TARE: transarterial radioembolization